LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article: Mpox vaccine and infection-driven human immune signatures.

    Cohn, Hallie / Bloom, Nathaniel / Cai, Gianna / Clark, Jordan / Tarke, Alison / Bermúdez-González, Maria C / Altman, Deena / Lugo, Luz Amarilis / Lobo, Francisco Pereira / Marquez, Susanna / Chen, Jin-Qiu / Ren, Wenlin / Qin, Lili / Crotty, Shane / Krammer, Florian / Grifoni, Alba / Sette, Alessandro / Simon, Viviana / Coelho, Camila H

    medRxiv : the preprint server for health sciences

    2023  

    Abstract: Background: Mpox (formerly known as monkeypox) outbreaks outside endemic areas peaked in July 2022, infecting > 85,000 people and raising concerns about our preparedness against this emerging viral pathogen. Licensed and approved for mpox, the JYNNEOS ... ...

    Abstract Background: Mpox (formerly known as monkeypox) outbreaks outside endemic areas peaked in July 2022, infecting > 85,000 people and raising concerns about our preparedness against this emerging viral pathogen. Licensed and approved for mpox, the JYNNEOS vaccine has fewer side effects than previous smallpox vaccines and demonstrated efficacy against mpox infection in humans. Comparing JYNNEOS vaccine- and mpox-induced immunity is imperative to evaluate JYNNEOS' immunogenicity and inform vaccine administration and design.
    Methods: We examined the polyclonal serum (ELISA) and single B cell (heavy chain gene and transcriptome data) antibody repertoires and T cells (AIM and ICS assays) induced by the JYNNEOS vaccine as well as mpox infection.
    Findings: Gene-level plasmablast and antibody responses were negligible and JYNNEOS vaccinee sera displayed minimal binding to recombinant mpox proteins and native proteins from the 2022 outbreak strain. In contrast, recent mpox infection (within 20-102 days) induced robust serum antibody responses to A29L, A35R, A33R, B18R, and A30L, and to native mpox proteins, compared to vaccinees. JYNNEOS vaccine recipients presented comparable CD4 and CD8 T cell responses against orthopox peptides to those observed after mpox infection.
    Interpretation: JYNNEOS immunization does not elicit a robust B cell response, and its immunogenicity may be mediated by T cells.
    Funding: Research reported in this publication was supported, in part, by the National Cancer Institute of the National Institutes of Health under Award Number U54CA267776, U19AI168631(VS), as well as institutional funds from the Icahn School of Medicine.
    Language English
    Publishing date 2023-03-09
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.03.07.23286701
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article: Development of a Novel Serological Assay for the Detection of Mpox Infection in Vaccinated Populations.

    Yates, Jennifer L / Hunt, Danielle T / Kulas, Karen E / Chave, Karen / Styer, Linda / Chakravarthi, Sandhya T / Cai, Gianna Y / Bermúdez-González, Maria C / Kleiner, Giulio / Altman, Deena / Srivastava, Komal / Simon, Viviana / Feihel, Dennis / McGowan, Joseph / Hogrefe, Wayne / Noone, Philip / Egan, Christina / Slifka, Mark K / Lee, William T

    medRxiv : the preprint server for health sciences

    2023  

    Abstract: In 2022 the World Health Organization declared a Public Health Emergency for an outbreak of mpox, the zoonotic Orthopoxvirus (OPV) affecting at least 103 non-endemic locations world-wide. Serologic detection of mpox infection is problematic, however, due ...

    Abstract In 2022 the World Health Organization declared a Public Health Emergency for an outbreak of mpox, the zoonotic Orthopoxvirus (OPV) affecting at least 103 non-endemic locations world-wide. Serologic detection of mpox infection is problematic, however, due to considerable antigenic and serologic cross-reactivity among OPVs and smallpox-vaccinated individuals. In this report, we developed a high-throughput multiplex microsphere immunoassay (MIA) using a combination of mpox-specific peptides and cross-reactive OPV proteins that results in the specific serologic detection of mpox infection with 93% sensitivity and 98% specificity. The New York State Non-Vaccinia Orthopoxvirus Microsphere Immunoassay is an important diagnostic tool to detect subclinical mpox infection and understand the extent of mpox spread in the community through retrospective analysis.
    Language English
    Publishing date 2023-04-24
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.04.18.23288419
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Development of a novel serological assay for the detection of mpox infection in vaccinated populations.

    Yates, Jennifer L / Hunt, Danielle T / Kulas, Karen E / Chave, Karen J / Styer, Linda / Chakravarthi, Sandhya T / Cai, Gianna Y / Bermúdez-González, Maria C / Kleiner, Giulio / Altman, Deena / Srivastava, Komal / Simon, Viviana / Feihel, Dennis / McGowan, Joseph / Hogrefe, Wayne / Noone, Philip / Egan, Christina / Slifka, Mark K / Lee, William T

    Journal of medical virology

    2023  Volume 95, Issue 10, Page(s) e29134

    Abstract: In 2022 the World Health Organization declared a Public Health Emergency for an outbreak of mpox, the zoonotic Orthopoxvirus (OPV) affecting at least 104 nonendemic locations worldwide. Serologic detection of mpox infection is problematic, however, due ... ...

    Abstract In 2022 the World Health Organization declared a Public Health Emergency for an outbreak of mpox, the zoonotic Orthopoxvirus (OPV) affecting at least 104 nonendemic locations worldwide. Serologic detection of mpox infection is problematic, however, due to considerable antigenic and serologic cross-reactivity among OPVs and smallpox-vaccinated individuals. In this report, we developed a high-throughput multiplex microsphere immunoassay using a combination of mpox-specific peptides and cross-reactive OPV proteins that results in the specific serologic detection of mpox infection with 93% sensitivity and 98% specificity. The New York State Non-Vaccinia Orthopoxvirus Microsphere Immunoassay is an important tool to detect subclinical mpox infection and understand the extent of mpox spread in the community through retrospective analysis.
    MeSH term(s) Humans ; Mpox (monkeypox) ; Retrospective Studies ; Asymptomatic Infections ; Biological Assay ; Cross Reactions ; Orthopoxvirus
    Language English
    Publishing date 2023-10-06
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S. ; Research Support, N.I.H., Extramural
    ZDB-ID 752392-0
    ISSN 1096-9071 ; 0146-6615
    ISSN (online) 1096-9071
    ISSN 0146-6615
    DOI 10.1002/jmv.29134
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1320: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study.

    Cohn, Hallie / Bloom, Nathaniel / Cai, Gianna Y / Clark, Jordan J / Tarke, Alison / Bermúdez-González, Maria C / Altman, Deena R / Lugo, Luz Amarilis / Lobo, Francisco Pereira / Marquez, Susanna / Chen, Jin-Qiu / Ren, Wenlin / Qin, Lili / Yates, Jennifer L / Hunt, Danielle T / Lee, William T / Crotty, Shane / Krammer, Florian / Grifoni, Alba /
    Sette, Alessandro / Simon, Viviana / Coelho, Camila H

    The Lancet. Infectious diseases

    2023  Volume 23, Issue 11, Page(s) 1302–1312

    Abstract: Background: Monkeypox virus has recently infected more than 88 000 people, raising concerns about our preparedness against this emerging viral pathogen. Licensed and approved for mpox, the JYNNEOS vaccine has fewer side-effects than previous smallpox ... ...

    Abstract Background: Monkeypox virus has recently infected more than 88 000 people, raising concerns about our preparedness against this emerging viral pathogen. Licensed and approved for mpox, the JYNNEOS vaccine has fewer side-effects than previous smallpox vaccines and has shown immunogenicity against monkeypox in animal models. This study aims to elucidate human immune responses to JYNNEOS vaccination compared with mpox-induced immunity.
    Methods: Peripheral blood mononuclear cells and sera were obtained from ten individuals vaccinated with one or two doses of JYNNEOS and six individuals diagnosed with monkeypox virus infection. Samples were obtained from seven individuals before vaccination to serve as a baseline. We examined the polyclonal serum (ELISA) and single B-cell (heavy chain gene and transcriptome data) antibody repertoires and T-cell responses (activation-induced marker and intracellular cytokine staining assays) induced by the JYNNEOS vaccine versus monkeypox virus infection.
    Findings: All participants were men between the ages of 21 and 60 years, except for one woman in the group of mpox-convalescent individuals, and none had previous orthopoxvirus exposure. All mpox cases were mild. Vaccinee samples were collected 6-33 days after the first dose and 5-40 days after the second dose. Mpox-convalescent samples were collected 20-102 days after infection. In vaccine recipients, gene-level plasmablast and antibody responses were negligible and sera displayed moderate binding to recombinant orthopoxviral proteins (A29L, A35R, E8L, A30L, A27L, A33R, B18R, and L1R) and native proteins from the 2022 monkeypox outbreak strain. By contrast, recent monkeypox virus infection (within 20-102 days) induced robust serum antibody responses to monkeypox virus proteins and to native monkeypox virus proteins from a viral isolate obtained during the 2022 outbreak. JYNNEOS vaccine recipients presented robust orthopoxviral CD4
    Interpretation: Infection with monkeypox virus resulted in robust B-cell and T-cell responses, whereas immunisation with JYNNEOS elicited more robust T-cell responses. These data can help to inform vaccine design and policies for preventing mpox in humans.
    Funding: National Cancer Institute (National Institutes of Health), National Institute of Allergy and Infectious Diseases (National Institutes of Health), and Icahn School of Medicine.
    MeSH term(s) United States ; Animals ; Male ; Female ; Humans ; Young Adult ; Adult ; Middle Aged ; Mpox (monkeypox)/prevention & control ; Smallpox Vaccine ; Leukocytes, Mononuclear ; Vaccines ; Vaccination ; Monkeypox virus
    Chemical Substances Smallpox Vaccine ; Vaccines
    Language English
    Publishing date 2023-07-17
    Publishing country United States
    Document type Observational Study ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, P.H.S. ; Research Support, Non-U.S. Gov't
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(23)00352-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5743: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Graph analysis of proton conduction pathways in scandium-doped barium zirconate.

    Gomez, Maria A / Brooks-Randall, Sophia / Cai, Gianna / Glass-Klaiber, Juniper / Jiang, Yuxin / Jo, Sungeun / Lin, Ziqing / Lin, Shiyun / Marcellus, Marsophia / Nguyen, Hong Anh / Pham, Trang / Wang, Yujing / Zhai, Fangyi / Gya, Parikshita / Khan, Samira

    The Journal of chemical physics

    2021  Volume 154, Issue 7, Page(s) 74711

    Abstract: Understanding the relationship between the acceptor dopant size and proton conductivity in barium zirconate, ... ...

    Abstract Understanding the relationship between the acceptor dopant size and proton conductivity in barium zirconate, BaZrO
    Language English
    Publishing date 2021-02-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 3113-6
    ISSN 1089-7690 ; 0021-9606
    ISSN (online) 1089-7690
    ISSN 0021-9606
    DOI 10.1063/5.0039103
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Bonn / Germany

    Z 4' 49/16: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma.

    Aleman, Adolfo / van Kesteren, Morgan / Zajdman, Ariel Kogan / Srivastava, Komal / Cognigni, Christian / Mischka, Jacob / Chen, Lucia Y / Upadhyaya, Bhaskar / Serebryakova, Kseniya / Nardulli, Jessica R / Lyttle, Neko / Kappes, Katerina / Jackson, Hayley / Gleason, Charles R / Oostenink, Annika / Cai, Gianna Y / Van Oekelen, Oliver / van Bakel, Harm / Sordillo, Emilia Mia /
    Cordon-Cardo, Carlos / Merad, Miriam / Jagannath, Sundar / Wajnberg, Ania / Simon, Viviana / Parekh, Samir

    EBioMedicine

    2023  Volume 98, Page(s) 104886

    Abstract: Background: The real-world impact of bivalent vaccines for wild type (WA.1) and Omicron variant (BA.5) is largely unknown in immunocompromised patients with Multiple Myeloma (MM). We characterize the humoral and cellular immune responses in patients ... ...

    Abstract Background: The real-world impact of bivalent vaccines for wild type (WA.1) and Omicron variant (BA.5) is largely unknown in immunocompromised patients with Multiple Myeloma (MM). We characterize the humoral and cellular immune responses in patients with MM before and after receiving the bivalent booster, including neutralizing assays to identify patterns associated with continuing vulnerability to current variants (XBB1.16, EG5) in the current post-pandemic era.
    Methods: We studied the humoral and cellular immune responses before and after bivalent booster immunization in 48 MM patients. Spike binding IgG antibody levels were measured by SARS-CoV-2 spike binding ELISA and neutralization capacity was assessed by a SARS-CoV-2 multi-cycle microneutralization assays to assess inhibition of live virus. We measured spike specific T-cell function using the QuantiFERON SARS-CoV-2 (Qiagen) assay as well as flow-cytometry based T-cell. In a subset of 38 patients, high-dimensional flow cytometry was performed to identify immune cell subsets associated with lack of humoral antibodies.
    Findings: We find that bivalent vaccination provides significant boost in protection to the omicron variant in our MM patients, in a treatment specific manner. MM patients remain vulnerable to newer variants with mutations in the spike portion. Anti-CD38 and anti-BCMA therapies affect the immune machinery needed to produce antibodies.
    Interpretation: Our study highlights varying immune responses observed in MM patients after receiving bivalent COVID-19 vaccination. Specifically, a subgroup of MM patients undergoing anti-CD38 and anti-BCMA therapy experience impairment in immune cells such DCs, B cells, NK cells and TFH cells, leading to an inability to generate adequate humoral and cellular responses to vaccination.
    Funding: National Cancer Institute (National Institutes of Health), National Institute of Allergy and Infectious Diseases (National Institutes of Health), NCI Serological Sciences Network for COVID-19 (SeroNet) and The Icahn School of Medicine at Mount Sinai.
    MeSH term(s) Humans ; Multiple Myeloma/therapy ; COVID-19 Vaccines ; SARS-CoV-2 ; COVID-19/prevention & control ; Immunoglobulin G ; Immunity ; Antibodies, Neutralizing ; Antibodies, Viral ; Vaccination
    Chemical Substances COVID-19 Vaccines ; Immunoglobulin G ; Antibodies, Neutralizing ; Antibodies, Viral
    Language English
    Publishing date 2023-11-22
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2851331-9
    ISSN 2352-3964
    ISSN (online) 2352-3964
    DOI 10.1016/j.ebiom.2023.104886
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7090: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top